New Breakthrough Therapy Designated for Thyroid Cancer and NSCLC

LOXO-292, which selectively targetsRET and has demonstrated preclinical activity against activatingRET fusions/mutations, holds promise.

Source: CancerNetwork - October 16, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news